Based on limited published evidence, PRXL2B encodes a peroxiredoxin-like oxidoreductase that catalyzes the reduction of prostamide H(2) to prostamide F(2α) using NADPH as a proton donor, with similar activity toward prostaglandin H(2) and prostaglandin F(2α). The protein localizes to multiple cellular compartments including mitochondria, endoplasmic reticulum, and cytoplasm. PRXL2B was identified as a minor component in a lipid metabolism-related predictive model for cutaneous melanoma progression 1, and showed altered expression in kidney tissue of offspring following oocyte vitrification 2, though its functional significance in these contexts remains unclear.